Evidence map›Paper›PMID 29250828›Full record

ArticleXenotransplantation2018

CD4+CD25

Avneesh K Singh, Joshua L Chan, Caleb N Seavey, Philip C Corcoran, Robert F Hoyt, Billeta G T Lewis, Marvin L Thomas, David L Ayares, Keith A Horvath, Muhammad M Mohiuddin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Xenotransplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. PD-L1Technology in cancer research & treatment
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Xenotransplantation: A New Era.Frontiers in immunology · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Avneesh K SinghCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Joshua L ChanCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Caleb N SeaveyCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Philip C CorcoranCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Robert F HoytCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Billeta G T LewisDepartment of Surgery, School of Medicine, University of Maryland, Baltimore, MD, USA.
Marvin L ThomasDivision of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, USA.
David L AyaresRevivicor, Inc., Blacksburg, VA, USA.
Keith A HorvathCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Muhammad M MohiuddinCardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-4654-783X
National Institutes of Health · USUniversity of Maryland, Baltimore · USVirginia Tech · US

Funding

Prolonging life-supported pig kidney and heart graft survival in baboons by suppressing inflammationU19AI090959 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2010 to 2024
$26.3M
NHLBI NIH HHS HHSN268201300001CNIAID NIH HHS U19 AI090959
6 · The paper itself

Abstract

backgroundCD4+CD25

methodsHeterotopic cardiac xenotransplantation was performed on baboons using hearts obtained from GTKO.hCD46 (n = 8) and GTKO.hCD46.TBM (n = 5) genetically modified pigs. Modified immunosuppression regimen included antithymocyte globulin (ATG), anti-CD20, mycophenolate mofetil (MMF), cobra venom factor (CVF), and costimulation blockade (anti-CD154/anti-CD40 monoclonal antibody). FACS analysis was performed on PBLs labeled with anti-human CD4, CD25, and FoxP3 monoclonal antibodies (mAb) to analyze the percentage of Treg cells in six baboons that survived longer than 2 months (range: 42-945 days) after receiving a pig cardiac xenograft.

resultsTotal WBC count was low due to immunosuppression in baboons who received cardiac xenograft from GTKO.hCD46 and GTKO.hCD46.hTBM donor pigs. However, absolute numbers of CD4+CD25

conclusionOur results suggest that regulatory T (Treg) cells may contribute to preventing or delaying xenograft rejection by controlling the activation and expansion of donor-reactive T cells, thereby masking the antidonor immune response, leading to long-term survival of cardiac xenografts.

Indexed as

Heart TransplantationTimeTransplantation, HeterologousAnimalsAnimals, Genetically ModifiedForkhead Transcription FactorsGraft RejectionGraft SurvivalHeterograftsImmune ToleranceImmunosuppression TherapyImmunosuppressive AgentsPapioSwineT-Lymphocytes, RegulatoryForkhead Transcription FactorsFOXP3 protein, humanImmunosuppressive Agentsimmunosuppressionregulatory T lymphocytesxenograft rejectionxenotransplantation

Identifiers

PMID29250828
PMCPMC13227586
OpenAlexW2804163185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.